Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BURLINGTON, Mass., May 01, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 2:10 p.m. EDT at the InterContinental Hotel in Boston.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
